Crystalline PPAR-delta Agonist Solid State Forms

The patent applies parameter changes by developing multiple crystalline forms (Form 1, Form 2, Form 3) and amorphous forms of the PPARδ agonist compound, each with distinct physical and chemical parameters such as solubility, stability, and bioavailability characteristics. This allows optimization of therapeutic efficacy while managing formulation challenges through selective use of different solid state forms

The patent employs composite materials by creating pharmaceutical compositions that combine the PPARδ agonist compound in specific crystalline or amorphous forms with excipients and other formulation components. These composite formulations are designed to enhance drug delivery, stability, and therapeutic performance while addressing the complexity of formulating a potent PPARδ agonist

The patent applies segmentation by systematically characterizing each crystalline form (Form 1, Form 2, Form 3) and amorphous form as distinct entities with unique identification criteria. Each form is defined by specific XRPD patterns, DSC thermograms, and other characterization data, enabling clear differentiation and quality control despite the multiplicity of forms

The patent uses intermediary characterization techniques such as XRPD, DSC, TGA, and FTIR as mediators to distinguish between different solid state forms of the PPARδ agonist. These analytical methods serve as intermediate tools that translate the complex structural differences between forms into measurable, comparable data for quality control and manufacturing verification